Looking for the best biotech penny stocks? The most important innovation of the 1990s was the internet — today, it would be a vaccine for COVID-19. If these times have anything to say about it ...

Gilead is laying off 149 workers in Foster City and Roche is laying off 108 workers in Santa Clara, adding to the mounting toll of biotech job cuts in the region. Gilead’s layoffs at its 333 Lakeside ...

Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a ...

Biotechnology may be the stuff that dreams are made of, but more recently, the sector has been a nightmare for investors. Biotech is coming off one of its worst weeks in several years after the ...

Biotech companies create drugs from living organisms, requiring a BLA for FDA approval. Pharma companies develop drugs from chemicals, needing an NDA for FDA approval. Many firms blend biotech and ...

Biotechnology is a broad discipline in which biological processes, organisms, cells or cellular components are exploited to develop new technologies. New tools and products developed by ...

(Reuters) -Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G" weight-loss drug candidate in a deal worth up to $2 billion.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

By Maggie Fick and Bhanvi Satija LONDON (Reuters) -Trump administration cuts across federal health agencies have sent shivers through a biotech industry already struggling through a prolonged downturn ...

Novo Nordisk has decided that it wants its own triple agonist, and is willing to hand over $200 million upfront to United Laboratories’ subsidiary United Biotechnology. In return for the global ...

Foresite Capital and M&G, among others. Editor's note: Bit.bio contends that is not a cell therapy biotech, but rather a synthetic biology company.

UBT251 targets GLP-1, GIP, and a third hormone, glucagon, hence the name "triple G". Rival Eli Lilly ... firms continue "to look to Chinese biotech names as a source for cheap early licensing ...